226 related articles for article (PubMed ID: 24714770)
1. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
Bhatt RS; Atkins MB
Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
[TBL] [Abstract][Full Text] [Related]
2. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
3. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.
Jonker L
Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424
[TBL] [Abstract][Full Text] [Related]
4. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.
Ardelean DS; Jerkic M; Yin M; Peter M; Ngan B; Kerbel RS; Foster FS; Letarte M
Angiogenesis; 2014 Jan; 17(1):129-46. PubMed ID: 24061911
[TBL] [Abstract][Full Text] [Related]
5. ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.
Alsina-Sanchís E; García-Ibáñez Y; Figueiredo AM; Riera-Domingo C; Figueras A; Matias-Guiu X; Casanovas O; Botella LM; Pujana MA; Riera-Mestre A; Graupera M; Viñals F
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1216-1229. PubMed ID: 29449337
[TBL] [Abstract][Full Text] [Related]
6. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
[TBL] [Abstract][Full Text] [Related]
7. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
Albiñana V; Recio-Poveda L; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2012 Jul; 108(1):41-53. PubMed ID: 22552254
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
[TBL] [Abstract][Full Text] [Related]
9. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P
J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445
[TBL] [Abstract][Full Text] [Related]
10. Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse.
Choi EJ; Walker EJ; Shen F; Oh SP; Arthur HM; Young WL; Su H
Cerebrovasc Dis; 2012; 33(6):540-7. PubMed ID: 22571958
[TBL] [Abstract][Full Text] [Related]
11. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.
Castonguay R; Werner ED; Matthews RG; Presman E; Mulivor AW; Solban N; Sako D; Pearsall RS; Underwood KW; Seehra J; Kumar R; Grinberg AV
J Biol Chem; 2011 Aug; 286(34):30034-46. PubMed ID: 21737454
[TBL] [Abstract][Full Text] [Related]
12. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.
Fernández-L A; Sanz-Rodriguez F; Blanco FJ; Bernabéu C; Botella LM
Clin Med Res; 2006 Mar; 4(1):66-78. PubMed ID: 16595794
[TBL] [Abstract][Full Text] [Related]
13. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
[TBL] [Abstract][Full Text] [Related]
14. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
[TBL] [Abstract][Full Text] [Related]
15. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway.
Pece-Barbara N; Vera S; Kathirkamathamby K; Liebner S; Di Guglielmo GM; Dejana E; Wrana JL; Letarte M
J Biol Chem; 2005 Jul; 280(30):27800-8. PubMed ID: 15923183
[TBL] [Abstract][Full Text] [Related]
16. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
[TBL] [Abstract][Full Text] [Related]
17. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1.
Yao Y; Zebboudj AF; Shao E; Perez M; Boström K
J Biol Chem; 2006 Nov; 281(45):33921-30. PubMed ID: 16950789
[TBL] [Abstract][Full Text] [Related]
18. Endoglin for tumor imaging and targeted cancer therapy.
Paauwe M; ten Dijke P; Hawinkels LJ
Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells.
Shao ES; Lin L; Yao Y; Boström KI
Blood; 2009 Sep; 114(10):2197-206. PubMed ID: 19506300
[TBL] [Abstract][Full Text] [Related]
20. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.
Mitchell D; Pobre EG; Mulivor AW; Grinberg AV; Castonguay R; Monnell TE; Solban N; Ucran JA; Pearsall RS; Underwood KW; Seehra J; Kumar R
Mol Cancer Ther; 2010 Feb; 9(2):379-88. PubMed ID: 20124460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
